Molecular Partners (MOLN) said Friday it priced an underwritten offering in the US of 3.6 million American depositary shares, each representing one ordinary share, at $5.49 per ADS for gross proceeds of about $20 million.
Proceeds from the offering, expected to close on Oct. 29, will be used to develop and expand the company's radiopharmaceutical pipeline and platform and for general corporate purposes.